These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27082853)

  • 21. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells.
    Foo JB; Saiful Yazan L; Tor YS; Wibowo A; Ismail N; Armania N; Cheah YK; Abdullah R
    J Ethnopharmacol; 2016 Jul; 187():195-204. PubMed ID: 27131434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines.
    Tiang JM; Butcher NJ; Minchin RF
    Cancer Med; 2015 Apr; 4(4):565-74. PubMed ID: 25627111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
    Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
    Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
    Nagata T; Shimada Y; Sekine S; Moriyama M; Hashimoto I; Matsui K; Okumura T; Hori T; Imura J; Tsukada K
    Breast Cancer; 2017 Mar; 24(2):326-335. PubMed ID: 27300169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model.
    Fritsche H; Heilmann T; Tower RJ; Hauser C; von Au A; El-Sheikh D; Campbell GM; Alp G; Schewe D; Hübner S; Tiwari S; Kownatzki D; Boretius S; Adam D; Jonat W; Becker T; Glüer CC; Zöller M; Kalthoff H; Schem C; Trauzold A
    Oncotarget; 2015 Apr; 6(11):9502-16. PubMed ID: 25909161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
    Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
    Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
    Ayub A; Yip WK; Seow HF
    Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.
    Browne G; Dragon JA; Hong D; Messier TL; Gordon JA; Farina NH; Boyd JR; VanOudenhove JJ; Perez AW; Zaidi SK; Stein JL; Stein GS; Lian JB
    Tumour Biol; 2016 Jul; 37(7):8825-39. PubMed ID: 26749280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation.
    Li W; Hardwick MJ; Rosenthal D; Culty M; Papadopoulos V
    Biochem Pharmacol; 2007 Feb; 73(4):491-503. PubMed ID: 17126818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.
    Park EJ; Min HY; Chung HJ; Hong JY; Kang YJ; Hung TM; Youn UJ; Kim YS; Bae K; Kang SS; Lee SK
    Cancer Lett; 2009 May; 277(2):133-40. PubMed ID: 19135778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer.
    Zhang L; Ma P; Sun LM; Han YC; Li BL; Mi XY; Wang EH; Song M
    Mol Carcinog; 2016 May; 55(5):768-77. PubMed ID: 25851994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins.
    Sumida T; Itahana Y; Hamakawa H; Desprez PY
    Cancer Res; 2004 Nov; 64(21):7886-92. PubMed ID: 15520195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells.
    Ravi M; Tentu S; Baskar G; Rohan Prasad S; Raghavan S; Jayaprakash P; Jeyakanthan J; Rayala SK; Venkatraman G
    BMC Cancer; 2015 Oct; 15():768. PubMed ID: 26499490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers.
    Pannu V; Mittal K; Cantuaria G; Reid MD; Li X; Donthamsetty S; McBride M; Klimov S; Osan R; Gupta MV; Rida PC; Aneja R
    Oncotarget; 2015 Apr; 6(12):10487-97. PubMed ID: 25868856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.